NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee D meeting minutes

**Minutes:** Confirmed

**Date:** Wednesday 4 September 2024

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Megan John (Chair) Present for all items
2. Dr Raju Reddy (Vice-chair) Present for all items
3. Martin Bradley Present for all items
4. Dr Matthew Bradley Items 1.1 to 4.3.2
5. Paul Caulfield Present for all items
6. Andrew Fox Present for all items
7. Dr Bernard Khoo Items 1.1 to 4.3.2
8. Dr Guy Makin Present for all items
9. Dr Philip Mallender Present for all items
10. Professor David Meads Present for all items
11. Giles Monnickendam Present for all items
12. Carole Pitkeathley Present for all items
13. Sophia Steer Present for all items
14. Dr Will Sullivan Present for all items
15. Dr Zenas Yiu Present for all items
16. Dr Savvas Vlachos (Observing) Present for all items

NICE staff (key players) present

Emily Crowe, Associate Director Items 1.1 to 4.3.2

Kate Moore, Project Manager Items 1.1 to 4.3.2

Albany Chandler, Heath Technology Assessment Adviser Items 1.1 to 4.3.2

Ana Willis, Heath Technology Assessment Analyst Items 1.1 to 4.3.2

Ross Dent, Associate Director Items 5.1.1 to 5.2.2

Louise Jafferally, Project Manager Items 5.1.1 to 5.2.2

Michelle Green, Heath Technology Assessment Adviser Items 5.1.1 to 5.2.2

Sally Lewis, Heath Technology Assessment Analyst Items 5.1.1 to 5.2.2

External assessment group representatives present

Nigel Fleeman, LRiG Items 1.1 to 4.2.1

Angela Stainthorpe, LRiG Items 1.1 to 4.2.1

Paul Tappenden, ScHARR Items 5.1.1 to 5.1.3

Mon Mon Yee, ScHARR Items 5.1.1 to 5.1.3

Clinical, Patient & NHS England experts present

Dr Yvonne Summers, Consultant Medical Oncologist, clinical expert nominated by Eli Lily Items 4.1.1 to 4.1.3

Peter Clark, CDF Clinical lead, NHSE Present for all items

Dr Elizabeth Toy, Consultant Clinical Oncologist, clinical expert nominated by AstraZeneca Items 5.1.1 to 5.1.3

Professor Eric Lim, Professor of Thoracic Surgery, clinical expert nominated by AstraZeneca Items 5.1.1 to 5.1.3

Dr Gini Harrison, Trustee, patient expert nominated by EGFR Positive UK Items 5.1.1 to 5.1.3

Angela Terry, Chair, EGFR Positive UK, patient expert nominated by EGFR Positive UK Items 5.1.1 to 5.1.3

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The Chair, Dr Megan John welcomed members of the committee and other attendees present to the meeting.
  2. The Chair noted apologies from Dr Ben Searle, Craig Cook, Dr Nathan Moore, Paula Parvulescu, Dr Robert Hodgson, Prof. Sofia Dias, Sue Wen Leo.

### News and announcements

* 1. The Chair welcomed new committee member Dr Savvas Vlachos.

### Minutes from the last meeting

* 1. The August 2024 committee minutes were not available for approval. It was agreed that they would be ready for approval at the October 2024 committee meeting.

### Appraisal of selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (MA review of TA760) [ID6293]

* 1. Part 1 – Open session
     1. The Chair, Dr Megan John, welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Eli Lilly.
     2. The Chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11480).
     3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Carole Pitkeathley, Dr Matthew Bradley, Martin Bradley.
  2. Part 2a – Closed session (company representatives, clinical experts and members of the public were asked to leave the meeting).
     1. The committee discussed confidential information submitted for this item.
  3. Part 2b – Closed session (external assessment group were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached through a vote by members.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11480>.

### Appraisal of osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (Review of TA761) [ID5120]

* 1. Part 1 – Open session
     1. The Chair, Dr Megan John, welcomed the invited experts, external assessment group representatives, members of the public and company representatives from AstraZeneca.
     2. The Chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11369).
     3. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by the Chair.
  2. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11369>.

### Date of the next meeting

The next meeting of the Technology Appraisal Committee D will be held on Thursday 3 October 2024 and will start promptly at 09:00am.